CO2022014499A2 - Moduladores de nlrp3 - Google Patents
Moduladores de nlrp3Info
- Publication number
- CO2022014499A2 CO2022014499A2 CONC2022/0014499A CO2022014499A CO2022014499A2 CO 2022014499 A2 CO2022014499 A2 CO 2022014499A2 CO 2022014499 A CO2022014499 A CO 2022014499A CO 2022014499 A2 CO2022014499 A2 CO 2022014499A2
- Authority
- CO
- Colombia
- Prior art keywords
- nlrp3 modulators
- nlrp3
- modulators
- disorders
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Amplifiers (AREA)
- Burglar Alarm Systems (AREA)
Abstract
En el presente documento se encuentran moduladores de NLRP3 y métodos para utilizar moduladores de NLRP3 en el tratamiento de enfermedades, trastornos o condiciones. En el presente documento también se describen composiciones farmacéuticas que contienen dichos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062990363P | 2020-03-16 | 2020-03-16 | |
PCT/US2021/022397 WO2021188450A1 (en) | 2020-03-16 | 2021-03-15 | Nlrp3 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022014499A2 true CO2022014499A2 (es) | 2023-02-16 |
Family
ID=77747550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0014499A CO2022014499A2 (es) | 2020-03-16 | 2022-10-12 | Moduladores de nlrp3 |
Country Status (15)
Country | Link |
---|---|
US (3) | US11603375B2 (es) |
EP (1) | EP4121059A4 (es) |
JP (1) | JP2023518044A (es) |
KR (1) | KR20220154165A (es) |
CN (1) | CN115605209A (es) |
AR (1) | AR121573A1 (es) |
AU (1) | AU2021237477A1 (es) |
BR (1) | BR112022018480A2 (es) |
CA (1) | CA3175729A1 (es) |
CL (1) | CL2022002531A1 (es) |
CO (1) | CO2022014499A2 (es) |
IL (1) | IL296488A (es) |
MX (1) | MX2022011576A (es) |
TW (1) | TW202200584A (es) |
WO (1) | WO2021188450A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022011576A (es) | 2020-03-16 | 2022-10-18 | Zomagen Biosciences Ltd | Moduladores de nlrp3. |
WO2022171185A1 (zh) * | 2021-02-10 | 2022-08-18 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20221627A1 (es) | 2015-02-16 | 2022-10-19 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de estos |
US11858922B2 (en) | 2016-02-16 | 2024-01-02 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
WO2018136890A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
AU2017416068A1 (en) * | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
EP3978489A1 (en) * | 2017-07-07 | 2022-04-06 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
EP3668842A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
AU2018317798A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP |
ES2927851T3 (es) | 2017-10-17 | 2022-11-11 | Novartis Ag | Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
SG11202013062VA (en) * | 2018-07-20 | 2021-02-25 | Hoffmann La Roche | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
AU2020314186A1 (en) | 2019-07-17 | 2022-02-24 | Zomagen Biosciences Ltd | NLRP3 modulators |
MX2022000646A (es) | 2019-07-17 | 2022-05-20 | Zomagen Biosciences Ltd | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). |
MX2022011576A (es) | 2020-03-16 | 2022-10-18 | Zomagen Biosciences Ltd | Moduladores de nlrp3. |
-
2021
- 2021-03-15 MX MX2022011576A patent/MX2022011576A/es unknown
- 2021-03-15 KR KR1020227035334A patent/KR20220154165A/ko active Search and Examination
- 2021-03-15 AR ARP210100650A patent/AR121573A1/es unknown
- 2021-03-15 AU AU2021237477A patent/AU2021237477A1/en active Pending
- 2021-03-15 EP EP21770604.3A patent/EP4121059A4/en active Pending
- 2021-03-15 US US17/202,047 patent/US11603375B2/en active Active
- 2021-03-15 CN CN202180035570.2A patent/CN115605209A/zh active Pending
- 2021-03-15 CA CA3175729A patent/CA3175729A1/en active Pending
- 2021-03-15 BR BR112022018480A patent/BR112022018480A2/pt not_active Application Discontinuation
- 2021-03-15 IL IL296488A patent/IL296488A/en unknown
- 2021-03-15 JP JP2022555714A patent/JP2023518044A/ja active Pending
- 2021-03-15 WO PCT/US2021/022397 patent/WO2021188450A1/en active Application Filing
- 2021-03-16 TW TW110109276A patent/TW202200584A/zh unknown
-
2022
- 2022-09-15 CL CL2022002531A patent/CL2022002531A1/es unknown
- 2022-10-12 CO CONC2022/0014499A patent/CO2022014499A2/es unknown
-
2023
- 2023-02-02 US US18/163,680 patent/US20230183258A1/en not_active Abandoned
- 2023-10-09 US US18/483,397 patent/US20240101571A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2022002531A1 (es) | 2023-03-31 |
US20210292336A1 (en) | 2021-09-23 |
EP4121059A1 (en) | 2023-01-25 |
IL296488A (en) | 2022-11-01 |
AR121573A1 (es) | 2022-06-15 |
CA3175729A1 (en) | 2021-09-23 |
US20230183258A1 (en) | 2023-06-15 |
TW202200584A (zh) | 2022-01-01 |
MX2022011576A (es) | 2022-10-18 |
US20240101571A1 (en) | 2024-03-28 |
AU2021237477A1 (en) | 2022-10-13 |
CN115605209A (zh) | 2023-01-13 |
KR20220154165A (ko) | 2022-11-21 |
BR112022018480A2 (pt) | 2022-11-29 |
EP4121059A4 (en) | 2023-12-13 |
JP2023518044A (ja) | 2023-04-27 |
US11603375B2 (en) | 2023-03-14 |
WO2021188450A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
UY38186A (es) | Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida | |
UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
CO2022014499A2 (es) | Moduladores de nlrp3 | |
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
BR112022000855A2 (pt) | Moduladores de nlrp3 | |
CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
CL2023002223A1 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
BR112021014566A2 (pt) | Moduladores de gpr35 | |
CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
EA202190766A1 (ru) | Иммуномодуляторы, их композиции и способы применения |